Uncategorized

Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Published

3 weeks ago

on

Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients.

The small-molecule drug, known as BIIB122, missed the study’s …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version